AnaptysBio (ANAB) hat im Frühjahr 2026 einen massiven strukturellen Wandel vollzogen und bietet Investoren nun ein völlig neues Risikoprofil. Mit…
The consensus price target hints at a 38.8% upside potential for AnaptysBio (ANAB). While empirical research shows that this sought-after…
After losing some value lately, a hammer chart pattern has been formed for AnaptysBio (ANAB), indicating that the stock has…
GSK PLCs (LSE:GSK, NYSE:GSK) oncology subsidiary TESARO has secured a partial legal victory after a Delaware court dismissed a counterclaim brought…
…
AnaptysBio (ANAB) delivered earnings and revenue surprises of +78.53% and +28.47%, respectively, for the quarter ended December 2025. Do the…
SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…
…
SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…
AnaptysBio stock hits 52-week high at 43.35 USD…
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…
GSK PLC (LSE:GSK, NYSE:GSK) has stepped up a dispute over rights to its fast-growing cancer drug Jemperli by having its US…
AnaptysBio (ANAB) delivered earnings and revenue surprises of +149.06% and +145.36%, respectively, for the quarter ended September 2025. Do the…
SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…
…
…
…
AnaptysBio (ANAB) delivered earnings and revenue surprises of 1.54% and 52.31%, respectively, for the quarter ended March 2025. Do the…
SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…
AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might…
AnaptysBio (ANAB) delivered earnings and revenue surprises of 55.28% and 324.09%, respectively, for the quarter ended December 2024. Do the…
SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…
SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…
AnaptysBio (ANAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend…
AnaptysBio stock soars on positive RA trial results…
SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…
SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…
Ecor1 Capitals Oleg Nodelman acquires $1.1m in AnaptysBio stock…
…
SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…
…
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…
…
The companys immediate future looks promising, as it has a drug that should get a clinical readout within months and…
…
SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…
…
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…
AnaptysBio (ANAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate…
A powerfully bullish new analyst take on the company helped it rally on the market.…
…
SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on…